# A Study of TEPEZZA Subcutaneous Administration in Healthy Adults

> **NCT06563856** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 37 (actual)

## Conditions studied

- Bioavailability
- Bioequivalence

## Interventions

- **DRUG:** TEPEZZA
- **DRUG:** EDP

## Key facts

- **NCT ID:** NCT06563856
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-22
- **Primary completion:** 2021-05-27
- **Final completion:** 2021-05-27
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2024-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06563856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06563856, "A Study of TEPEZZA Subcutaneous Administration in Healthy Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06563856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*